Macy Jin, MD profile page

Dr. Macy Jin joined WuXi Biologics in April 2023 as a subject matter expert in biotherapeutic drug discovery. She brings over 20 years of experience from Wyeth/Pfizer, where she advanced from individual contributor to group leader of display platforms and project team leader in antibody discovery, with a focus on oncology, autoimmune and rare diseases. Macy has extensive technical expertise, including 10 years in hybridoma and over 10 years in display-based antibody discovery. She is a key inventor of phage panning and screening strategies that led to the discovery of Marstacimab (Hympavzi), the first FDA-approved anti-tissue factor pathway inhibitor (TFPI) antibody for Hemophilia in 2024.